Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis
- 1 July 2015
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 4 (4) , 350-357
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyThe Lancet Neurology, 2014
- Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5DMultiple Sclerosis Journal, 2013
- The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosisQuality of Life Research, 2012
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosisEuropean Journal of Neurology, 2010
- The psychosocial effect of multiple sclerosis: The impact of relapsesJournal of the Neurological Sciences, 2007
- The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measureBrain, 2001
- Quality of Life and Its Relationship to Brain Lesions and Atrophy on Magnetic Resonance Images in 60 Patients With Multiple SclerosisArchives of Neurology, 2000
- Comparison of the EQ-5D and SF-12 Health Surveys in a General Population Survey in Alberta, CanadaMedical Care, 2000
- VALIDITY OF EUROQOL—A GENERIC HEALTH STATUS INSTRUMENT—IN PATIENTS WITH RHEUMATOID ARTHRITISRheumatology, 1994
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990